Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company's product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company's SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Symbol: NASDAQ:HRTX
- CUSIP: N/A
- Web: www.herontx.com
- Market Cap: $820.19 million
- Outstanding Shares: 54,138,000
- 50 Day Moving Avg: $15.81
- 200 Day Moving Avg: $14.97
- 52 Week Range: $12.21 - $20.85
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -6.50
- P/E Growth: -0.17
- Annual Revenue: $13.42 million
- Price / Sales: 61.12
- Book Value: $1.28 per share
- Price / Book: 11.84
- EBIDTA: ($174,140,000.00)
- Return on Equity: -451.80%
- Return on Assets: -152.23%
- Debt-to-Equity Ratio: 0.36%
- Current Ratio: 2.82%
- Quick Ratio: 2.72%
- Average Volume: 772,647 shs.
- Beta: 2.07
- Short Ratio: 11.55
Frequently Asked Questions for Heron Therapeutics (NASDAQ:HRTX)
What is Heron Therapeutics' stock symbol?
Heron Therapeutics trades on the NASDAQ under the ticker symbol "HRTX."
How were Heron Therapeutics' earnings last quarter?
Heron Therapeutics, Inc. (NASDAQ:HRTX) issued its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.90) by $0.10. The firm had revenue of $8.51 million for the quarter, compared to analyst estimates of $4.53 million. View Heron Therapeutics' Earnings History.
Where is Heron Therapeutics' stock going? Where will Heron Therapeutics' stock price be in 2017?
9 brokers have issued 12-month price objectives for Heron Therapeutics' shares. Their forecasts range from $21.00 to $41.00. On average, they expect Heron Therapeutics' share price to reach $31.43 in the next twelve months. View Analyst Ratings for Heron Therapeutics.
What are analysts saying about Heron Therapeutics stock?
Here are some recent quotes from research analysts about Heron Therapeutics stock:
- 1. According to Zacks Investment Research, "Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA. " (7/12/2017)
- 2. Cowen and Company analysts commented, "Earlier today Heron stock dropped as much as 8.5% on seemingly no news." (5/26/2017)
- 3. Cantor Fitzgerald analysts commented, "Expensive 1Q: HRTX reported 1Q17 EPS of ($1.00), below our estimated ($0.83). The difference is mainly attributed to higher than expected R&D spend, though we believe that should taper off through the year, providing some flexibility in cash runway. HRTX finished the quarter with $165M in cash." (5/11/2017)
- 4. Needham & Company LLC analysts commented, "We initiate coverage of Heron Therapeutics, a commercial-stage specialty biopharma focused on novel extended-release injectables, at Buy with a $28 PT. HRTX made the transition to a commercial co. in 4Q16 with the launch of Sustol for CINV. Cinvanti, on file with FDA (likely 4Q17 PDUFA), will round out the CINV franchise. The main value driver, HTX-011, is an extended-release combination of bupivacaine/meloxicam in development for post-op pain management. HTX-011 successfully completed a comprehensive ph 2 program in various surgical procedures demonstrating superior efficacy to placebo and bupivacaine. HTX-011 will begin ph 3 development in 2017. Our valuation looks at the differentiated CINV assets and cash balance (~$215MM) as a floor value for HRTX, while the potential of HTX-011 remains mostly undervalued." (2/27/2017)
Are investors shorting Heron Therapeutics?
Heron Therapeutics saw a decrease in short interest in the month of August. As of August 15th, there was short interest totalling 12,723,565 shares, a decrease of 8.6% from the July 31st total of 13,920,842 shares. Based on an average trading volume of 505,331 shares, the short-interest ratio is presently 25.2 days. Currently, 23.9% of the shares of the stock are short sold.
Who are some of Heron Therapeutics' key competitors?
Some companies that are related to Heron Therapeutics include Foundation Medicine (FMI), Biohaven Pharmaceutical Holding Co Ltd (BHVN), Immunomedics (IMMU), Genus plc (GNS), Momenta Pharmaceuticals (MNTA), Medpace Holdings (MEDP), Global Blood Therapeutics (GBT), Esperion Therapeutics (ESPR), Genomic Health (GHDX), Cellectis S.A. (CLLS), Arena Pharmaceuticals (ARNA), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), Albany Molecular Research (AMRI), BeyondSpring (BYSI), Enanta Pharmaceuticals (ENTA), TG Therapeutics (TGTX) and Spectrum Pharmaceuticals (SPPI).
Who are Heron Therapeutics' key executives?
Heron Therapeutics' management team includes the folowing people:
- Kevin C. Tang, Independent Chairman of the Board
- Robert Harvey Rosen, President, Director
- Barry D. Quart Pharm.D., Chief Executive Officer, Director
- Robert E. Hoffman, Chief Financial Officer, Senior Vice President - Finance, Principal Accounting Officer
- Kimberly J. Manhard, Executive Vice President - Drug Development
- David L. Szekeres, Senior Vice President, General Counsel, Business Development, Corporate Secretary
- Michael A. Adam Ph.D., Senior Vice President - Regulatory Affairs and Quality
- Thomas B. Ottoboni Ph.D., Senior Vice President - Pharmaceutical and Preclinical Research and Development
- Sean T. Ristine, Vice President - Human Resources
- Christian Waage, Director
Who owns Heron Therapeutics stock?
Heron Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Tang Capital Management LLC (0.00%), Franklin Resources Inc. (0.00%), FMR LLC (0.00%), Janus Henderson Group PLC (0.00%), Vanguard Group Inc. (0.00%) and State Street Corp (0.00%). Company insiders that own Heron Therapeutics stock include Kevin C Tang, Kimberly Manhard and Robert Rosen. View Institutional Ownership Trends for Heron Therapeutics.
Who sold Heron Therapeutics stock? Who is selling Heron Therapeutics stock?
Heron Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., State Street Corp, Tang Capital Management LLC, Brandywine Global Investment Management LLC, California State Teachers Retirement System and Old West Investment Management LLC. View Insider Buying and Selling for Heron Therapeutics.
Who bought Heron Therapeutics stock? Who is buying Heron Therapeutics stock?
Heron Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Vanguard Group Inc., Rubric Capital Management LP, BlueCrest Capital Management Ltd, Royce & Associates LP, Northern Trust Corp, National Asset Management Inc. and Mesirow Financial Investment Management Inc.. View Insider Buying and Selling for Heron Therapeutics.
How do I buy Heron Therapeutics stock?
Shares of Heron Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Heron Therapeutics' stock price today?
MarketBeat Community Rating for Heron Therapeutics (NASDAQ HRTX)MarketBeat's community ratings are surveys of what our community members think about Heron Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Heron Therapeutics stock can currently be purchased for approximately $15.15.
Earnings History for Heron Therapeutics (NASDAQ:HRTX)Earnings History by Quarter for Heron Therapeutics (NASDAQ HRTX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/9/2017||Q2 2017||($0.90)||($0.80)||$4.53 million||$8.51 million||View||N/A|
|5/10/2017||Q1 2017||($0.94)||($1.00)||$1.96 million||$3.63 million||View||N/A|
|2/23/2017||Q4 2016||($1.17)||($1.22)||$1.07 million||$1.28 million||View||N/A|
Earnings Estimates for Heron Therapeutics (NASDAQ:HRTX)
2017 EPS Consensus Estimate: ($3.56)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Heron Therapeutics (NASDAQ:HRTX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Heron Therapeutics (NASDAQ:HRTX)
Insider Ownership Percentage: 20.31%Insider Trades by Quarter for Heron Therapeutics (NASDAQ:HRTX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|4/24/2017||Kimberly Manhard||VP||Sell||21,542||$15.33||$330,238.86|| |
|1/19/2017||Kevin C Tang||Director||Buy||2,459,016||$12.20||$29,999,995.20|| |
|8/10/2016||Robert Rosen||Insider||Sell||100,000||$23.30||$2,330,000.00|| |
|4/21/2016||Robert Rosen||President||Sell||200,000||$23.23||$4,646,000.00|| |
|6/10/2015||Kevin C Tang||Director||Buy||121,212||$24.75||$2,999,997.00|| |
|6/2/2015||Kevin C Tang||Director||Buy||150,000||$20.62||$3,093,000.00|| |
|6/1/2015||Kimberly Manhard||Director||Sell||2,708||$21.17||$57,328.36|| |
|6/25/2014||Barry D Quart||CEO||Buy||10,000||$11.75||$117,500.00|| |
|6/25/2014||Kevin C Tang||Director||Buy||510,638||$11.75||$5,999,996.50|| |
|11/20/2013||Barry D Quart||CEO||Buy||1,000,000||$0.40||$400,000.00|| |
Headline Trends for Heron Therapeutics (NASDAQ:HRTX)
Latest Headlines for Heron Therapeutics (NASDAQ:HRTX)
|Interesting HRTX Put And Call Options For November 17th|
www.thestreet.com - September 20 at 12:40 AM
|Heron Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference - Business Wire (press release)|
www.businesswire.com - September 19 at 7:37 PM
|Heron Therapeutics, Inc. (HRTX) Receives Average Recommendation of "Buy" from Brokerages|
www.americanbankingnews.com - September 16 at 6:46 PM
|Notable Friday Option Activity: LEA, SEAS, HRTX|
www.nasdaq.com - September 16 at 1:07 AM
| Brokerages Anticipate Heron Therapeutics, Inc. (HRTX) Will Post Quarterly Sales of $8.25 Million|
www.americanbankingnews.com - September 15 at 9:48 AM
|Heron Therapeutics, Inc. – Value Analysis (NASDAQ:HRTX) : September 14, 2017|
finance.yahoo.com - September 14 at 6:11 AM
|Heron Therapeutics, Inc. (HRTX) Expected to Post Earnings of -$0.87 Per Share|
www.americanbankingnews.com - September 13 at 6:20 AM
|Heron Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HRTX-US : September 12, 2017|
finance.yahoo.com - September 12 at 11:47 PM
|What Does Heron Therapeutics Inc’s (HRTX) Share Price Indicate?|
finance.yahoo.com - September 9 at 1:12 AM
|Heron Therapeutics Shows Rising Relative Strength; Still Shy Of Key Threshold|
finance.yahoo.com - September 6 at 7:34 PM
|Heron Therapeutics Shows Rising Price Performance With Jump To 82 RS Rating|
finance.yahoo.com - August 31 at 5:56 AM
|Heron Therapeutics Trying To Close In On Key Technical Benchmark|
finance.yahoo.com - August 29 at 8:11 PM
|Heron Therapeutics, Inc. (HRTX) Sees Significant Decrease in Short Interest|
www.americanbankingnews.com - August 27 at 3:12 AM
|Heron Therapeutics, Inc. (HRTX) Upgraded to Hold by BidaskClub|
www.americanbankingnews.com - August 26 at 4:56 PM
| Analysts Anticipate Heron Therapeutics, Inc. (HRTX) Will Announce Earnings of -$0.87 Per Share|
www.americanbankingnews.com - August 25 at 8:18 PM
|FY2017 EPS Estimates for Heron Therapeutics, Inc. (HRTX) Cut by Analyst|
www.americanbankingnews.com - August 23 at 8:38 AM
|Heron Therapeutics, Inc. (HRTX) Given Average Recommendation of "Buy" by Analysts|
www.americanbankingnews.com - August 22 at 9:06 PM
|Heron Therapeutics' (HRTX) "Buy" Rating Reiterated at Jefferies Group LLC|
www.americanbankingnews.com - August 20 at 10:46 PM
|Heron Therapeutics, Inc. (HRTX) PT Set at $31.00 by Cantor Fitzgerald|
www.americanbankingnews.com - August 19 at 11:32 PM
|Heron Therapeutics, Inc. (HRTX) Cut to Sell at BidaskClub|
www.americanbankingnews.com - August 19 at 12:38 AM
|Heron Therapeutics: Our Next Pick - Seeking Alpha|
seekingalpha.com - August 14 at 7:51 PM
|Brokers Issue Forecasts for Heron Therapeutics, Inc.'s Q3 2017 Earnings (HRTX)|
www.americanbankingnews.com - August 14 at 2:50 AM
|FY2020 EPS Estimates for Heron Therapeutics, Inc. (HRTX) Decreased by Jefferies Group|
www.americanbankingnews.com - August 11 at 4:50 PM
|Heron Therapeutics, Inc. (HRTX) Rating Reiterated by Noble Financial|
www.americanbankingnews.com - August 11 at 10:14 AM
|Should You Buy Heron Therapeutics (HRTX) Ahead of Earnings|
finance.yahoo.com - August 11 at 3:02 AM
|Heron Therapeutics, Inc. (HRTX) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPS|
www.americanbankingnews.com - August 11 at 12:40 AM
|Heron Therapeutics (HRTX) Initiates Phase 3 Program for HTX-011 in Postoperative Pain Following Successful End-of-Phase 2 Meeting with FDA|
www.streetinsider.com - August 10 at 12:53 AM
|Heron Therapeutics (HRTX) Initiates Phase 3 Program for HTX-011 in Postoperative Pain Following Successful End-of ... - StreetInsider.com|
www.streetinsider.com - August 9 at 7:50 PM
|Heron Therapeutics Announces Initiation of Phase 3 Program for HTX-011 in Postoperative Pain Following Successful End-of-Phase 2 Meeting with FDA|
finance.yahoo.com - August 9 at 7:50 PM
|Heron Therapeutics Reports Financial Results for the Three and Six Months Ended June 30, 2017 and Recent Corporate Progress|
finance.yahoo.com - August 9 at 7:50 PM
|Heron Therapeutics reports 2Q loss|
finance.yahoo.com - August 9 at 7:50 PM
| Brokerages Anticipate Heron Therapeutics, Inc. (NASDAQ:HRTX) Will Post Quarterly Sales of $4.53 Million|
www.americanbankingnews.com - August 9 at 7:24 AM
|-$0.95 Earnings Per Share Expected for Heron Therapeutics Inc (NASDAQ:HRTX) This Quarter|
www.americanbankingnews.com - August 7 at 10:34 AM
|Heron Therapeutics, Inc. (HRTX) PT Set at $40.00 by Cowen and Company|
www.americanbankingnews.com - August 6 at 6:28 PM
|Heron Therapeutics, Inc. (HRTX) Receives Consensus Rating of "Buy" from Analysts|
www.americanbankingnews.com - July 28 at 9:09 PM
|Short Interest in Heron Therapeutics, Inc. (NASDAQ:HRTX) Decreases By 9.8%|
www.americanbankingnews.com - July 28 at 2:21 AM
|ETFs with exposure to Heron Therapeutics, Inc. : July 24, 2017|
finance.yahoo.com - July 24 at 11:08 PM
|Zacks: Analysts Anticipate Heron Therapeutics, Inc. (HRTX) Will Post Quarterly Sales of $4.53 Million|
www.americanbankingnews.com - July 20 at 3:48 PM
|Zacks: Brokerages Anticipate Heron Therapeutics, Inc. (HRTX) Will Post Earnings of -$0.95 Per Share|
www.americanbankingnews.com - July 18 at 9:55 AM
|Heron Therapeutics, Inc. (NASDAQ:HRTX) Stock Rating Reaffirmed by Jefferies Group LLC|
www.americanbankingnews.com - July 15 at 3:35 PM
|ETFs with exposure to Heron Therapeutics, Inc. : July 14, 2017|
finance.yahoo.com - July 15 at 12:43 AM
|HRTX Crosses Above Key Moving Average Level|
www.nasdaq.com - July 14 at 2:53 AM
|Heron Therapeutics Shows Potential In The Chemotherapy-Induced-Nausea Market|
seekingalpha.com - July 10 at 7:34 PM
|Heron Therapeutics, Inc. – Value Analysis (NASDAQ:HRTX) : July 7, 2017|
finance.yahoo.com - July 8 at 11:30 AM
|Heron Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HRTX-US : July 6, 2017|
finance.yahoo.com - July 7 at 6:14 AM
|Heron Therapeutics, Inc. (NASDAQ:HRTX) Given Consensus Recommendation of "Buy" by Analysts|
www.americanbankingnews.com - July 3 at 6:52 PM
|Heron Therapeutics, Inc. Expected to Post FY2017 Earnings of ($3.32) Per Share (HRTX)|
www.americanbankingnews.com - June 28 at 8:02 AM
|Heron Therapeutics, Inc. Forecasted to Post FY2018 Earnings of ($2.23) Per Share (HRTX)|
www.americanbankingnews.com - June 27 at 10:14 AM
|Heron Therapeutics, Inc. (HRTX) Rating Increased to Sell at ValuEngine|
www.americanbankingnews.com - June 24 at 11:32 PM
| Brokerages Anticipate Heron Therapeutics, Inc. (HRTX) Will Post Quarterly Sales of $4.53 Million|
www.americanbankingnews.com - June 24 at 11:02 AM
Heron Therapeutics (HRTX) Chart for Friday, September, 22, 2017